Can we improve the negative predictive value of faecal calprotectin for the diagnosis of IBS in primary care?

Abstract

Introduction Recent data has established faecal calprotectin (FC) as a highly sensitive and specifi c test for detecting infl am-matory bowel disease (IBD) in patients referred to secondary care. 1 Computer modelling has shown that the high negative predictive value (NPV) could be used to support the diagnosis of irritable bowel syndrome (IBS) in primary care, and that, after Bayesian analysis, the NPV could be increased further with higher 'cut off' of FC. 2 Aim This observational cohort study aims to test this hypothesis. Study population All patients with a borderline FC result (50-100 mg/f) from May 2005 to 2009. Patient data were cross referenced to electronic patient records, radiology (PACS), endoscopy and histology data sets using SnomedCT codes (T655260, TT67000-68930) to Oct 2010. Exclusion criteria: previous IBD diagnosis, <16 year at study entry or a previous FC results >150 mg/f. Primary end point Diagnosis of IBD by standard clinical criteria during follow-up Results From 5943 patients within the entire faecal calprotec-tin dataset, 433 (7%) were between the values of 50-100 mg/f and met the inclusion criteria. Of 433 (62% female, median age 48 year, range 18-90 and 60% aged <55 year) diarrhoea (56%) and alarm symptoms (11%) were the most frequent indications for testing. The majority of patients were also consequently investigated by lower GI endoscopy (n=230, 53%), or radiology (abdominal CT or MRI, n=112, 26%) and 66 (15%) had both tests. Endoscopic biopsies were taken in 104/230 (45%) procedures, but which in only 10 patients confi rmed a diagnosis of IBD. In all 10 patients the pretest probability of IBD was high, and in 9/10 a repeat FC had increased (median rise 35mg/f) in contrast to the other 52 patients with a repeat test, for who values remained the same (± 15 mg/f) or fell. During